Skip to main content
SpringerLink
Log in

Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumors

  • Chapter
  • First Online:
Radioguided Surgery

Abstract

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, but the incidence is rising. Surgery plays a central role in its management, as it is the only potentially curative treatment option for limited primary and recurrent disease and is critical in the surgical debulking and cytoreduction of advanced recurrent and metastatic disease. For preoperative detection of disease, gamma-emitting radiopharmaceuticals are available which can also be intraoperatively used for radioguided surgery. Most experience exists for 111In-octreotide, a radiopharmaceutical targeting agent specifically binding to somatostatin receptors expressed on the tumor cell surface. In comparison to traditional intraoperative inspection and palpation techniques, intraoperative localization using 111In-octreotide has demonstrated high sensitivity and detection rates. Recently, first promising results have been reported for utilization of intraoperative scintigraphic imaging in GEP-NETs in addition to more commonplace gamma probe localization.

Portions of the contents of this chapter are adapted from 1 prior article:

(1) Hall et al.: Intraoperative utilization of a portable large field of view gamma camera and handheld gamma detection probe for radioguided localization and prediction of complete surgical resection of gastrinoma: Proof of concept. J Am Coll Surg. 2015;221(2):300–308. doi: http://dx.doi.org/10.1016/j.jamcollsurg.2015.03.047

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Diez M, Teule A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol. 2013;26:29–36.

    PubMed  PubMed Central  Google Scholar 

  2. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691–703. doi:10.1016/j.bpg.2013.01.006.

    Article  CAS  PubMed  Google Scholar 

  3. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–97. doi:10.1002/cncr.29099.

    Article  PubMed  Google Scholar 

  4. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18, vii. doi:10.1016/j.ecl.2010.12.005.

    Google Scholar 

  5. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin oncol. 2008;26:3063–72. doi:10.1200/JCO.2007.15.4377.

    Article  PubMed  Google Scholar 

  6. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. doi:10.1016/S1470-2045(07)70410-2.

    Article  CAS  PubMed  Google Scholar 

  7. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424. doi:10.1159/000085237.

    Article  CAS  PubMed  Google Scholar 

  8. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32. doi:10.1136/gutjnl-2011-300831.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bendelow J, Apps E, Jones LE, Poston GJ. Carcinoid syndrome. Eur J Surg Oncol. 2008;34:289–96. doi:10.1016/j.ejso.2007.07.202.

    Article  CAS  PubMed  Google Scholar 

  10. Boudreaux JP. Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS). Endocrinol Metab Clin North Am. 2011;40:163–71, ix. doi:10.1016/j.ecl.2010.12.004.

    Google Scholar 

  11. Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:819–31. doi:10.1016/j.bpg.2012.12.005.

    Article  PubMed  Google Scholar 

  12. Partelli S, Maurizi A, Tamburrino D, Baldoni A, Polenta V, Crippa S, et al. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171:R153–62. doi:10.1530/EJE-14-0173.

    Article  CAS  PubMed  Google Scholar 

  13. Plockinger U, Gustafsson B, Ivan D, Szpak W, Davar J. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology. 2009;90:190–3. doi:10.1159/000225947.

    Article  PubMed  Google Scholar 

  14. Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol. 2005;19:659–73. doi:10.1016/j.bpg.2005.05.002.

    Article  CAS  PubMed  Google Scholar 

  15. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741–51. doi:10.1002/cncr.24065.

    Article  PubMed  Google Scholar 

  16. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:311–24. doi:10.1016/j.beem.2004.11.001.

    Article  CAS  PubMed  Google Scholar 

  17. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135–56. doi:10.1159/000335629.

    Article  CAS  PubMed  Google Scholar 

  18. Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008;87:20–30. doi:10.1159/000109876.

    Article  PubMed  Google Scholar 

  19. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology. 2008;87:31–9. doi:10.1159/000111036.

    Article  CAS  PubMed  Google Scholar 

  20. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006;84:165–72. doi:10.1159/000098008.

    Article  CAS  PubMed  Google Scholar 

  21. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.

    Article  CAS  PubMed  Google Scholar 

  22. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–9. doi:10.1056/NEJM199011013231805.

    Article  CAS  PubMed  Google Scholar 

  23. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902. doi:10.1210/jcem.86.2.7194.

    Article  CAS  PubMed  Google Scholar 

  24. Kvols LK, Brown ML, O'Connor MK, Hung JC, Hayostek RJ, Reubi JC, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology. 1993;187:129–33. doi:10.1148/radiology.187.1.8383865.

    Article  CAS  PubMed  Google Scholar 

  25. Ober K, Akerstrom G, Rindi G, Jelic S. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;21 Suppl 5:v223–7.

    Article  Google Scholar 

  26. Gulec SA, Baum R. Radio-guided surgery in neuroendocrine tumors. J Surg Oncol. 2007;96:309–15. doi:10.1002/jso.20868.

    Article  PubMed  Google Scholar 

  27. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol. 1999;10 Suppl 4:182–4.

    Article  PubMed  Google Scholar 

  28. Albertario S, Forti P, Bianchi C, Morone G, Tinozzi FP, Moglia P, et al. Radioguided surgery for gastrinoma: a case report. Tumori. 2002;88:S41–3.

    CAS  PubMed  Google Scholar 

  29. Benevento A, Dominioni L, Carcano G, Dionigi R. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe. Semin Surg Oncol. 1998;15:239–44.

    Article  CAS  PubMed  Google Scholar 

  30. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. 2009;46:13–106. doi:10.1067/j.cpsurg.2008.09.001.

    Article  PubMed  Google Scholar 

  31. Hosoya Y, Satoh K, Hironaka M, Nokubi M, Kurashina K, Shibayama C, et al. Multiple gastric carcinoids associated with parietal cell hyperplasia: intraoperative detection with a radiolabeled somatostatin analog. Gastric cancer. 2008;11:123–6. doi:10.1007/s10120-008-0457-8.

    Article  PubMed  Google Scholar 

  32. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26–34.

    Article  CAS  PubMed  Google Scholar 

  33. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460–6. doi:10.1007/s00259-005-0006-1.

    Article  CAS  PubMed  Google Scholar 

  34. Modlin IM, Cornelius E, Lawton GP. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg. 1995;130:367–73; discussion 73–4.

    Article  CAS  PubMed  Google Scholar 

  35. Ohrvall U, Westlin JE, Nilsson S, Juhlin C, Rastad J, Lundqvist H, et al. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer. 1997;80:2490–4.

    Article  CAS  PubMed  Google Scholar 

  36. Ohrvall U, Westlin JE, Kjellberg F, Nilsson S, Juhlin C, Rastad J, et al. A gamma detector probe with ex vivo detection of carcinoid tumors superior to intraoperative palpation. Cancer. 1997;80:2495–500.

    Article  CAS  PubMed  Google Scholar 

  37. Schirmer WJ, O'Dorisio TM, Schirmer TP, Mojzisik CM, Hinkle GH, Martin EW. Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery. 1993;114:745–51; discussion 51–2.

    CAS  PubMed  Google Scholar 

  38. Woltering EA, Barrie R, O'Dorisio TM, O'Dorisio MS, Nance R, Cook DM. Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery. 1994;116:1139–46; discussion 46–7.

    CAS  PubMed  Google Scholar 

  39. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW. Bringing advanced medical imaging into the operative arena could revolutionize the surgical care of cancer patients. Expert Rev Med Devices. 2008;5:663–7. doi:10.1586/17434440.5.6.663.

    Article  PubMed  Google Scholar 

  40. Hall NC, Povoski SP, Zhang J, Knopp MV, Martin Jr EW. Use of intraoperative nuclear medicine imaging technology: strategy for improved patient management. Expert Rev Med Devices. 2013;10:149–52. doi:10.1586/erd.13.2.

    Article  CAS  PubMed  Google Scholar 

  41. Povoski SP, Neff RL, Mojzisik CM, O'Malley DM, Hinkle GH, Hall NC, et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009;7:11. doi:10.1186/1477-7819-7-11.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Ellison EC, Gower WR, Elkhammas E, Woltering EA, Sparks J, O'Dorisio TM, et al. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201–995). Am J Med. 1986;81:56–64.

    Article  CAS  PubMed  Google Scholar 

  43. Geelhoed GW, Bass BL, Mertz SL, Becker KL. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia. Surgery. 1986;100:962–70.

    CAS  PubMed  Google Scholar 

  44. Carnaille B, Nocaudie M, Pattou F, Huglo D, Deveaux M, Marchandise X, et al. Scintiscans and carcinoid tumors. Surgery. 1994;116:1118–21; discussion 21–2.

    CAS  PubMed  Google Scholar 

  45. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, et al. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion. 1994;55 Suppl 3:54–9.

    Article  PubMed  Google Scholar 

  46. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nuc Med. 1992;33:652–8.

    CAS  Google Scholar 

  47. Adams S, Baum RP, Hertel A, Wenisch HJ, Staib-Sebler E, Herrmann G, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nuc Med. 1998;39:1155–60.

    CAS  Google Scholar 

  48. Banzo J, Vidal-Sicat S, Prats E, Galofre G, Razola P, Mane S, et al. In-111 DTPA octreotide scintigraphy and intraoperative gamma probe detection in the diagnosis and treatment of residual lymph node metastases of a rectal carcinoid tumor. Clin Nucl Med. 2005;30:308–11.

    Article  CAS  PubMed  Google Scholar 

  49. Benjegard SA, Forssell-Aronsson E, Wangberg B, Skanberg J, Nilsson O, Ahlman H. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Eur J Nucl Med. 2001;28:1456–62. doi:10.1007/s002590100600.

    Article  CAS  PubMed  Google Scholar 

  50. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8. doi:10.1007/s00259-010-1473-6.

    Article  PubMed  Google Scholar 

  51. Serrano Vicente J, Dominguez Grande ML, Infante De La Torre JR, Duran Barquero C, Garcia Bernardo L, Rayo Madrid JI, et al. Radioguided surgery of intestinal carcinoid tumor relapse. Role of SPECT-CT. Revista espanola de medicina nuclear. 2010;29:177–80. doi:10.1016/j.remn.2010.02.011.

    Article  CAS  PubMed  Google Scholar 

  52. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol. 2010;17:291–7. doi:10.1016/j.acra.2009.08.015.

    Article  PubMed  Google Scholar 

  53. van Hulsteijn LT, Corssmit EP, van der Hiel B, Smit JW, Stokkel MP. Is there a role for radioguided surgery with iodine-labeled metaiodobenzylguanidine in resection of neuroendocrine tumors? Clin Nucl Med. 2012;37:1083–8. doi:10.1097/RLU.0b013e318266cb3d.

    Article  PubMed  Google Scholar 

  54. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–6. doi:10.1007/s00268-002-6663-3.

    Article  PubMed  Google Scholar 

  55. Wang YZ, Diebold A, Woltering E, King H, Boudreaux JP, Anthony LB, et al. Radioguided exploration facilitates surgical cytoreduction of neuroendocrine tumors. J Gastrointest Surg. 2012;16:635–40. doi:10.1007/s11605-011-1767-4.

    Article  PubMed  Google Scholar 

  56. Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R, et al. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging. 2005;49:237–44.

    CAS  PubMed  Google Scholar 

  57. Fettich J, Pepse S, Snoj M, Zitko-Krhin M, Markovic M. 99mTc-EDDA/HAYNIC-TOC is suitable radiopharmaceutical for radioguided surgery of neuroendocrine tumours. In: Trends in radiopharmaceuticals (ISTR-2005), vol. 1. Vienna: IAEA; 2007. p. 183–4.

    Google Scholar 

  58. Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33. doi:10.1007/s00259-006-0113-7.

    Article  CAS  PubMed  Google Scholar 

  59. Taieb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977–95. doi:10.1007/s00259-012-2215-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Meyer-Rochow GY, Schembri GP, Benn DE, Sywak MS, Delbridge LW, Robinson BG, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17:392–400. doi:10.1245/s10434-009-0850-5.

    Article  PubMed  Google Scholar 

  61. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46. doi:10.1007/s00259-010-1545-7.

    Article  PubMed  Google Scholar 

  62. van Hulsteijn LT, van der Hiel B, Smit JW, Stokkel MP, Corssmit EP. Intraoperative detection of ganglioneuromas with 123I-MIBG. Clin Nucl Med. 2012;37:768–71. doi:10.1097/RLU.0b013e31825add9b.

    Article  PubMed  Google Scholar 

  63. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83.

    Article  CAS  PubMed  Google Scholar 

  64. Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, et al. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med. 2012;37:142–7. doi:10.1097/RLU.0b013e3182291de8.

    Article  PubMed  Google Scholar 

  65. Aitken DR, Thurston MO, Hinkle Jr GH, Martin DT, Haagensen Jr DE, Houchens D, et al. Portable gamma probe for radioimmune localization of experimental colon tumor xenografts. J Surg Res. 1984;36:480–9.

    Article  CAS  PubMed  Google Scholar 

  66. Aitken DR, Hinkle GH, Thurston MO, Tuttle SE, Martin DT, Olsen J, et al. A gamma-detecting probe for radioimmune detection of CEA-producing tumors. Successful experimental use and clinical case report. Dis Colon Rectum. 1984;27:279–82.

    Article  CAS  PubMed  Google Scholar 

  67. Desai B, Elatre W, Quinn DI, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011;36:961–2. doi:10.1097/RLU.0b013e3182291d1a.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Desai DC, Arnold M, Saha S, Hinkle G, Soble D, Fry J, et al. Correlative whole-body FDG-PET and intraoperative gamma detection of FDG distribution in colorectal cancer. Clin Positron Iimaging. 2000;3:189–96.

    Article  Google Scholar 

  69. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin Jr EW. Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. World J Surg Oncol. 2007;5:143. doi:10.1186/1477-7819-5-143.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Martinez DA, King DR, Romshe C, Lozano RA, Morris JD, O'Dorisio MS, et al. Intraoperative identification of parathyroid gland pathology: a new approach. J Pediatr Surg. 1995;30:1306–9.

    Article  CAS  PubMed  Google Scholar 

  71. Povoski SP, Hall NC, Martin Jr EW, Walker MJ. Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma. World J Surg Oncol. 2008;6:1. doi:10.1186/1477-7819-6-1.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Povoski SP, Hall NC, Murrey Jr DA, Chow AZ, Gaglani JR, Bahnson EE, et al. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience. World J Surg Oncol. 2011;9:152. doi:10.1186/1477-7819-9-152.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Povoski SP, Chapman GJ, Murrey Jr DA, Lee R, Martin Jr EW, Hall NC. Intraoperative detection of (1)(8)F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria. BMC Cancer. 2013;13:98. doi:10.1186/1471-2407-13-98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Povoski SP, Hall NC, Murrey Jr DA, Sharp DS, Hitchcock CL, Mojzisik CM, et al. Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov. 2013;20:59–69. doi:10.1177/1553350612438416.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Povoski SP, Murrey Jr DA, Smith SM, Martin Jr EW, Hall NC. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues. BMC Cancer. 2014;14:453. doi:10.1186/1471-2407-14-453.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, Tuttle SE, Hinkle GH, Rousseau M, et al. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum. 1987;30:761–4.

    Article  CAS  PubMed  Google Scholar 

  77. Hall NC, Nichols SD, Povoski SP, James IA, Wright CL, Harris R, et al. Intraoperative Use of a portable large field of view gamma camera and handheld gamma detection probe for radioguided localization and prediction of complete surgical resection of gastrinoma: proof of concept. J Am Coll Surg. 2015;221:300–8. doi:10.1016/j.jamcollsurg.2015.03.047.

    Article  PubMed  Google Scholar 

  78. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–23; discussion 24–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. McCarthy DM, Hyman PE. Effect of isopropamide on response to oral cimetidine in patients with Zollinger--Ellison syndrome. Dig Dis Sci. 1982;27:353–9.

    Article  CAS  PubMed  Google Scholar 

  80. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–44. doi:10.1056/NEJM199908263410902.

    Article  CAS  PubMed  Google Scholar 

  81. Norton JA, Jensen RT. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg. 2007;205:S34–7. doi:10.1016/j.jamcollsurg.2007.06.320.

    Article  PubMed  Google Scholar 

  82. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9. doi:10.1097/01.sla.0000234802.44320.a5.

    PubMed  PubMed Central  Google Scholar 

  83. Chapman GJ, Povoski SP, Hall NC, Murrey Jr DA, Lee R, Martin Jr EW. Comparison of two threshold detection criteria methodologies for determination of probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery. BMC Cancer. 2014;14:667. doi:10.1186/1471-2407-14-667.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Thurston MO. Development of the gamma detecting probe for radioimmunoguided surgery. In: Martin EW, editor. Radioimmunoguided Surgery (RIGS) in the detection and treatment of colorectal cancer, 1st ed. Austin: R.G. Landes Company; 1994. p. 41–65.

    Google Scholar 

  85. Siman W, Kappadath SC. Performance characteristics of a new pixelated portable gamma camera. Med Phys. 2012;39:3435–44. doi:10.1118/1.4718874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Nathan C. Hall MD, PhD

  2. Department of Nuclear Medicine, University Hospital of Würzburg, Würzburg, Germany

    Christina Bluemel MD

  3. Department of Nuclear Medicine, Hospital Clinic-Barcelona, Barcelona, Spain

    Sergi Vidal-Sicart MD, PhD

  4. Division of Surgical Oncology, Department of Surgery, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA

    Stephen P. Povoski MD

Authors
  1. Nathan C. Hall MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Bluemel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergi Vidal-Sicart MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen P. Povoski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathan C. Hall MD, PhD .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Würzburg, Department of Nuclear Medicine, Würzburg, Germany

    Ken Herrmann

  2. The University of Sydney, Melanoma Institute Australia, North Sydney, New South Wales, Australia

    Omgo E. Nieweg

  3. Arthur G. James Canc Hosp Richard J. Sol, The Ohio State Univ Comp Canc CTR, Columbus, Ohio, USA

    Stephen P. Povoski

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hall, N.C., Bluemel, C., Vidal-Sicart, S., Povoski, S.P. (2016). Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumors. In: Herrmann, K., Nieweg, O., Povoski, S. (eds) Radioguided Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-26051-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26051-8_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26049-5

  • Online ISBN: 978-3-319-26051-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation